Advertisement

Topics

Latest "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Stories

10:35 EST 21st January 2019 | BioPortfolio

Here are the most relevant search results for "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" found in our extensive news archives from over 250 global news sources.

More Information about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal for you to read. Along with our medical data and news we also list Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Clinical Trials, which are updated daily. BioPortfolio also has a large database of Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal Companies for you to search.

Showing "Marketed Nasal Strip Placebo Nasal Strip Prototype Nasal" News Articles 1–25 of 2,400+

Monday 21st January 2019

ResMed’s First Top-of-Head CPAP Mask, AirFit N30i, Now Available across U.S.

AirFit N30i adds a top-of-head mask-to-tube connection to ResMed’s expanding CPAP mask portfolio, helps the wearer move and sleep in any position New “cradle” cushion sits under the nose, designed to reduce facial markings and irritation ResMed (NYSE: RMD, ASX: RMD), today introduced AirFit N30i, its first ...


Antibe Therapeutics Receives Approval to Initiate Part Two of Phase 2B Dose-Ranging, Efficacy Study for ATB-346

Antibe Therapeutics Inc. ("Antibe") (TSXV:ATE, OTCQB:ATBPF), a leader in developing safer therapeutics for pain and inflammation, is pleased to announce that it has received approval from Health Canada to initiate the second part of its Phase 2B dose-ranging, efficacy study for its lead drug, ATB-346. The primary objective of the study is to evaluate ...

CO.DON AG and Bauerfeind France SARL sign term sheet for cooperation in marketing and sales in France

DGAP-News: CO.DON AG / Key word(s): Expansion 21.01.2019 / 10:00 The issuer is solely responsible for the content of this announcement. CO.DON AG and Bauerfeind France SARL sign term sheet for cooperation in marketing and sales in France Berlin / Teltow, 21 January 2019 - CO.DON AG and Bauerfeind France SARL have agreed on a partnership to open up the French market and distribute CO.D...


Biomarkers and Companion Diagnostics in Oncology [Report Updated: 17122018] Prices from USD $7995

Biomarkers and Companion Diagnostics in OncologySummaryA biomarker is a defined molecular characteristic, for example a genetic mutation, that can tell a physician more about a patient's disease state, or how they might respond to treatment. Predictive biomarkers indicate how likely a patient is to respond to a treatment, and are used in clinical decision making. In some cases, a patient must poss...

Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth [Report Updated: 01012019] Prices from USD $4995

Global Women's Health Drugs Market to 2024 Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive GrowthSummaryThe women's health therapy area covers medical disorders that affect females only, primarily disorders of the female reproductive system, including those associated with menstruation, conception, pregnancy, childbirth and menopause. Many o...

PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets [Report Updated: 01072018] Prices from USD $2995

PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream TargetsSummaryGBI Research's latest report, PI3K Signaling Pathway Analysis: A Shifting Marketed and Pipeline Product Landscape, as Blockbusters Expire and Development Moves Towards Downstream Targets, provides a comprehensive assessment of the market...

Sunday 20th January 2019

US FDA Approves ONTRUZANT® (trastuzumab-dttb), Samsung Bioepis’ First Oncology Medicine in the United States

Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved ONTRUZANT® (trastuzumab-dttb), a biosimilar referencing HERCEPTIN® 1 (trastuzumab), across all eligible indications, namely adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer and metastatic gastric cancer or gastroesophag...

Saturday 19th January 2019

Week in Review: Yantai's MabPlex Raises $59 Million to Expand CDMO Services

Deals and Financings  MabPlex, a Yantai biologics CDMO, completed a $59 million Series A round for its biologics development and manufacturing services; Tyto Care, an Israeli telehealth company, raised $9 million from a group that includes China investors for its internet-enabled "home doctor visits"; Ascletis Pharma of Hangzhou acquired China rights to a Suzhou Alphamab anti-PD-L1 candidate...

Friday 18th January 2019

[Corrections] Correction to Lancet Neurol 2019; 18: 145–54

LeWitt PA, Hauser RA, Pahwa R, et al, on behalf of the SPAN-PD Study Investigators. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol 2019; 18: 145–54—In this Article, CVT-301 was incorrectly spelled in some instances in the Summary an...

Automated Route Finding (and Patent Busting)

Here’s another look at retrosynthesis software, building on the earlier Chematica paper that looked at generating new routes to known compounds. This is a more detailed look at the same idea, using the software to both analyze the existing routes to marketed drugs (and the patent landscape around them) and to come up with new

Synmosa Biopharma Corp 4114 Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 23102018] Prices from USD $250

SummarySynmosa Biopharma Corp Synmosa is a pharmaceutical company that manufactures, markets and distributes generic medicines. The company produces nonpharmaceutical products such as cosmeceutical and nutrition products, and food supplements in effervescent tablet and granule forms. It offers products in the therapeutic areas of cardiovascular, respiratory, urology, sex hormone, gynecology and ca...

Lilly stops promoting cancer drug after shock trial failure

Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop promoting the already-marketed medicine. Lartruvo (olaratum...

Thursday 17th January 2019

Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data at ASCO 2019 Gastrointestinal Cancers Symposium (ASCO GI)

Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today that the safety and efficacy data in the gastrectomy patient subgroup of the global Phase III trial TAGS evaluating LONSURF® (trifluridine/tipiracil, TAS-102) in patients with metastatic gastric cancer (mGC) are consistent with the over...

Acorda Announces The Lancet Neurology Publication of Phase 3 Data for INBRIJA™ (levodopa inhalation powder)

SPAN℠-PD, the efficacy and safety study of INBRIJA (CVT-301), showed significant improvement in motor function during OFF periods in people with Parkinson’s on a carbidopa/levodopa regimen INBRIJA was approved in the U.S. in Dec. 2018 and is expected to be available by prescription in Q1 2019 Acorda Therapeutics...

Adaptive Biotechnologies Announces Medicare Coverage of the clonoSEQ® Assay for MRD Testing in Patients with Multiple Myeloma and Acute Lymphoblastic Leukemia at Multiple Timepoints Throughout Treatment and Remission

Adaptive Biotechnologies, an immune driven-medicine company, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) and leader in assessing diagnostic technologies through its MolDX program, has established coverage of the clonoSEQ® Assay for Medicare patients with multiple myeloma and B-cell acute lymphoblastic leukemia (ALL). clon...

Ironshore Pharmaceuticals Announces Appointment of Dr. Lewis Warrington as Vice President / Head of Medical Affairs

Ironshore Pharmaceuticals, Inc. (“Ironshore”), a wholly owned subsidiary of Highland Therapeutics Inc. (“Highland”) and a leader in the commercialization of novel treatments for

Spectrum Pharmaceuticals Sells Marketed Portfolio to Acrotech Biopharma to Focus on New and Innovative Cancer Therapies

HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI) announced today that it has entered into a definitive agreement to sell its portfolio of seven FDA-approved hematology/oncology products to Acrotech Biopharma L.L.C. Acrotech Biopharma is a New Jersey-based wholly-owned subsidiary of Aurobindo Pharma USA Inc. “This divestiture marks a major strategic shi...

Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M

CEO Joe Turgeon said in an interview that the company aims to focus more on developing drugs for larger, broader and more lucrative oncology markets.

Spectrum divesting marketed products to focus on late-stage programs

Gender difference in the effects of cacao polyphenols on blood pressure and glucose/lipid metabolism in prediabetic subjects: a double-blinded, randomized, placebo-controlled crossover trial

Tricida Announces Hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer

Tricida, Inc. (Nasdaq: TCDA), today announced the hiring of Susannah Cantrell, Ph.D., as Chief Commercial Officer and Senior Vice President. Dr. Cantrell will lead Tricida’s commercial planning and operations functions. “Susannah brings a breadth and depth of strategic and operational experience to Tricida that we believe will enable us t...

Omeros Finalizes with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy

--Additional Positive Data Reported from Second Cohort in Phase 2 Trial-- Omeros Corporation (Nasdaq: OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclon...

Myomo® to Present at Noble Capital Markets’ 15th Annual Investor Conference

Myomo, Inc. (NYSE American: MYO) (“Myomo,” or the “Company”), a wearable medical robotics company, today announced that it will be presenting at NobleCon15 - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida on Monday, January 28th at 10:30 AM EST - Studio 3. Chairman and Chief Executive Officer Paul R....

$SPPI Sells Marketed Portfolio to Acrotech Biopharma to Focus on New and Innovative Therapies for Cancer Patients. Will receive $160M upfront https://www.businesswire.com/news/home/20190117005355/en/Spectrum-Pharmaceuticals-Sells-Marketed-Portfolio-Acrote

$SPPI Sells Marketed Portfolio to Acrotech Biopharma to Focus on New and Innovative Therapies for Cancer Patients. Will receive $160M upfront https://www.businesswire.com/news/home/20190117005355/en/Spectrum-Pharmaceuticals-Sells-Marketed-Portfolio-Acrotech-Biopharma …

Aerpio Pharmaceuticals Announces Completion of Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy

Aerpio Pharmaceuticals, Inc. (Nasdaq: ARPO), a biopharmaceutical company focused on developing compounds that activate Tie2 to treat ocular diseases and diabetic complications, today announced the completion of patient dosing in the Company’s TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio’s lead candidate, ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks